Literature DB >> 262800

Impairment of reticuloendothelial system function with sepsis and its improvement with ATP-MgCl2 plus glucose administration.

I H Chaudry, H Hirasawa, A E Baue.   

Abstract

Peritonitis in rats was produced by cecal ligation and puncture. Sixteen hours following cecal ligation and puncture, the gangrenous cecum was removed and the animals received either 4 ml saline (nontreated), 0.75 ATP-MgCl2 (100 mumoles ATP plus 50 mumoles MgCl2), and 2.0 ml of 50% glucose or 2.0 ml of 50% mannitol and 1.25 ml saline. Two hours after the removal of the cecum, RES function was evaluated by measuring the intravascular clearance of a 131 I triolein-labeled gelatinized test lipid emulsion. The intravascular half-time (t1/2) in the nontreated animals was double that of sham-operated animals, suggesting that significant depression in RES function occurred during sepsis. Administration of ATP-MgCl2 plus glucose following sepsis resulted in t1/2 values similar to those of sham-operated animals, indicating that the impairment of pagocytic activity of the RES was reversed with treatment. The beneficial effect of treatment following sepsis does not appear to be due to hypertonicity, since administration of 50% mannitol failed to decrease the t1/2. The precise mechanism of the beneficial effect of ATP-MgCl2 + glucose on restoration of RES function is not known.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 262800

Source DB:  PubMed          Journal:  Adv Shock Res        ISSN: 0195-878X


  2 in total

1.  Interleukin-1β Modulates Synaptic Transmission and Synaptic Plasticity During the Acute Phase of Sepsis in the Senescence-Accelerated Mouse Hippocampus.

Authors:  Koji Hoshino; Yuka Uchinami; Yosuke Uchida; Hitoshi Saito; Yuji Morimoto
Journal:  Front Aging Neurosci       Date:  2021-02-10       Impact factor: 5.750

Review 2.  Epigenetic and metabolic programming of innate immunity in sepsis.

Authors:  Vidula Vachharajani; Charles E McCall
Journal:  Innate Immun       Date:  2019-04-18       Impact factor: 2.680

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.